Application of Immuno-PET in Antibody–Drug Conjugate Development

Application of Immuno-PET in Antibody–Drug Conjugate Development

Targeted therapies hold great promise for cancer treatment and may exhibit even greater efficacy when combined with patient selection tools. The clinical impact of identifying likely responders includes reducing the number of unnecessary and ineffective therapies as well as more accurately determini...

Full description

Bibliographic Details
Main Authors:	Kendra S. Carmon PhD, Ali Azhdarinia PhD
Format:	Article
Language:	English
Published:	Hindawi - SAGE Publishing 2018-10-01
Series:	Molecular Imaging
Online Access:	https://doi.org/10.1177/1536012118801223

Similar Items

Adamantane/Cucurbituril: A Potential Pretargeted Imaging Strategy in Immuno-PET
by: Martin G. Strebl PhD, et al.
Published: (2018-10-01)

Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab
by: Elaine M. Jagoda PhD, et al.
Published: (2019-04-01)

Development of Antibody Immuno-PET/SPECT Radiopharmaceuticals for Imaging of Oncological Disorders—An Update
by: Jonatan Dewulf, et al.
Published: (2020-07-01)

Development of the covalent antibody-DNA conjugates technology for detection of IgE and IgM antibodies by immuno-PCR.
by: Artem V Maerle, et al.
Published: (2019-01-01)

Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate
by: Christian Brand, et al.
Published: (2018-08-01)

Purinergic Receptors of the Central Nervous System: Biology, PET Ligands, and Their Applications
by: Hamideh Zarrinmayeh PhD, et al.
Published: (2020-06-01)

Preclinical PET Neuroimaging of [C]Bexarotene
by: Benjamin H. Rotstein PhD, et al.
Published: (2016-08-01)

Immuno-PET for Clinical Theranostic Approaches
by: Clément Bailly, et al.
Published: (2016-12-01)

Detecting Demyelination by PET: The Lesion as Imaging Target
by: Pedro Brugarolas PhD, et al.
Published: (2018-07-01)

Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates
by: Julien Dugal-Tessier, et al.
Published: (2021-02-01)

Immuno-PET Molecular Imaging of RANKL in Cancer
by: Jonatan Dewulf, et al.
Published: (2021-04-01)

Development of [F]FPy-WL12 as a PD-L1 Specific PET Imaging Peptide
by: Wojciech G. Lesniak PhD, et al.
Published: (2019-06-01)

Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET
by: T. Lee Collier PhD, et al.
Published: (2017-10-01)

Controllable Drug Delivery by Na+/K+ ATPase α1 Targeting Peptide Conjugated DSPE-PEG Nanocarriers for Breast Cancer
by: Yayan Yang BS, et al.
Published: (2021-06-01)

Emerging PET Radiotracers and Targets for Imaging of Neuroinflammation in Neurodegenerative Diseases: Outlook Beyond TSPO
by: Vidya Narayanaswami PhD, et al.
Published: (2018-09-01)

Anti-human PD-L1 Nanobody for Immuno-PET Imaging: Validation of a Conjugation Strategy for Clinical Translation
by: Jessica Bridoux, et al.
Published: (2020-09-01)

Multiscale Mask R-CNN–Based Lung Tumor Detection Using PET Imaging
by: Rui Zhang PhD, et al.
Published: (2019-07-01)

Comparison of New Tau PET-Tracer Candidates With [F]T808 and [F]T807
by: Lieven Declercq Pharmacist, et al.
Published: (2016-01-01)

Recent advances of antibody drug conjugates for clinical applications
by: Pengxuan Zhao, et al.
Published: (2020-09-01)

PET/SPECT Molecular Probes for the Diagnosis and Staging of Nonalcoholic Fatty Liver Disease
by: Tuo Shao PhD, et al.
Published: (2019-09-01)

Quantification of Cerenkov Luminescence Imaging (CLI) Comparable With 3-D PET Standard Measurements
by: Frezghi Habte PhD, et al.
Published: (2018-07-01)

Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates
by: Guolan Lu, et al.
Published: (2020-11-01)

Lights and Shadows in Immuno-Oncology Drug Development
by: Milana Bergamino Sirvén, et al.
Published: (2021-02-01)

Molecular Imaging of Hydrolytic Enzymes Using PET and SPECT
by: Brian P. Rempel BSc, PhD, et al.
Published: (2017-09-01)

Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma
by: Jakub Radocha, et al.
Published: (2021-03-01)

Impact of moving target on measurement accuracy in 3D and 4D PET imaging—a phantom study
by: Yunfeng Cui, PhD, et al.
Published: (2017-01-01)

Targeting Stereotactic Body Radiotherapy on Metabolic PET- and Immuno-PET-Positive Vertebral Metastases
by: Baptiste Pichon, et al.
Published: (2020-11-01)

Detection of Neuroinflammation in a Rat Model of Subarachnoid Hemorrhage Using [F]DPA-714 PET Imaging
by: Clément Thomas MD, et al.
Published: (2016-04-01)

Antibody–Drug Conjugates for Cancer Therapy
by: Umbreen Hafeez, et al.
Published: (2020-10-01)

Antibody–Drug Conjugates: The Last Decade
by: Nicolas Joubert, et al.
Published: (2020-09-01)

Antibody Drug Conjugates for Cancer Therapy
by: S M Gheibi hayat, et al.
Published: (2017-07-01)

Acquired Resistance to Antibody-Drug Conjugates
by: Denis M. Collins, et al.
Published: (2019-03-01)

Antibody–Drug Conjugates for Cancer Therapy
by: Adam C. Parslow, et al.
Published: (2016-07-01)

Antibody Drug Conjugates as Cancer Therapeutics
by: Pamela A. Trail
Published: (2013-02-01)

Antibody–Drug Conjugate to Treat Meningiomas
by: Kai Chen, et al.
Published: (2021-05-01)

Clinical Pharmacology of Antibody-Drug Conjugates
by: Iftekhar Mahmood
Published: (2021-05-01)

Evaluation of a BGO-Based PET System for Single-Cell Tracking Performance by Simulation and Phantom Studies
by: Yu Ouyang PhD, et al.
Published: (2016-05-01)

Pyrrolobenzodiazepine Antibody-Drug Conjugates Designed for Stable Thiol Conjugation
by: R. James Christie, et al.
Published: (2017-11-01)

Development of Antibody–Drug Conjugates Using DDS and Molecular Imaging
by: Masahiro Yasunaga, et al.
Published: (2017-09-01)

Bioprocess development of antibody-drug conjugate production for cancer treatment.
by: Jianfa Ou, et al.
Published: (2018-01-01)

Cannot write session to /tmp/vufind_sessions/sess_5k43vmbe632v1ikpetuhs19brf